PARIS--(BUSINESS WIRE)--Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

The TESLA trial was unable to support a benefit to thrombectomy for stroke patients with large-core infarcts identified on noncontrast CT within 24 hours. Unlike other studies, endovascular therapy in ...

A stroke — either a blockage of blood flow to the brain or bleeding in the brain — is a medical emergency that requires immediate treatment. The two types of stroke are treated differently but can ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance ...

The largest dataset to date on stroke detection with the Swoop® system demonstrates the ability to identify small strokes rapidly and reliably, reinforcing its clinical value for acute care and ...

The clinical syndrome produced by a stroke is determined by the artery or arteries that are occluded. Blood is supplied to the brain by two major sets of arteries, the anterior and posterior ...

The publication includes a subset of data from the ACTION PMR stroke study and provides early evidence that the Swoop® system is a promising tool for enabling critical stroke treatment choices in ...

Advanced brain imaging is expanding stroke treatment windows, enabling selected patients beyond 24 hours to benefit ...

Expanded eligibility for advanced stroke therapies and new recommendations for diagnosing and treating stroke in children and adults are among the major updates in the new 2026 Guideline for the Early ...

Brainomix announced today that it added $6.5 million (£4.8 million) in an extension to its Series C financing round.